Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TSHA Taysha Gene Therapies Inc
- Stocks
- Healthcare
- NASDAQ: TSHA
Price (delayed)
$2.79
Market cap
$598.91M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.34
Enterprise value
$539.26M
Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, Taysha aims to rapidly translate our treatments from bench to
Highlights
Taysha Gene Therapies's EPS has increased by 31% YoY and by 6% QoQ
Taysha Gene Therapies's net income has increased by 26% YoY and by 2.8% QoQ
Taysha Gene Therapies's quick ratio has surged by 61% YoY but it has decreased by 2.2% QoQ
The company's equity fell by 23% QoQ but it rose by 2.2% YoY
The gross profit has decreased by 49% YoY and by 13% QoQ
Taysha Gene Therapies's revenue has decreased by 49% YoY and by 13% QoQ
Key stats
What are the main financial stats of TSHA
Market
Valuations
Earnings
Shares outstanding
214.66M
Market cap
$598.91M
Enterprise value
$539.26M
Price to earnings (P/E)
N/A
Price to book (P/B)
10.39
Price to sales (P/S)
104.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
74.65
Revenue
$7.22M
Gross profit
$7.22M
Operating income
-$88.55M
Net income
-$86.77M
EBIT
-$86.67M
EBITDA
-$84.24M
Free cash flow
-$84.06M
Per share
Balance sheet
Liquidity
EPS
-$0.34
EPS diluted
-$0.34
Free cash flow per share
-$0.31
Book value per share
$0.27
Revenue per share
$0.03
TBVPS
$0.51
Total assets
$138.36M
Total liabilities
$83.3M
Debt
$59.55M
Equity
$55.06M
Working capital
$98.15M
Debt to equity
1.08
Current ratio
5.35
Quick ratio
5.28
Net debt/EBITDA
0.71
Margins
Efficiency
Dividend
EBITDA margin
-1,166.1%
Gross margin
100%
Net margin
-1,201.1%
Operating margin
-1,225.8%
Return on assets
-51.1%
Return on equity
-107%
Return on invested capital
-166.6%
Return on capital employed
-74.8%
Return on sales
-1,199.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TSHA stock price
How has the Taysha Gene Therapies stock price performed over time
Intraday
0.36%
1 week
14.34%
1 month
8.14%
1 year
-24.18%
YTD
61.27%
QTD
100.72%
Financial performance
How have Taysha Gene Therapies's revenue and profit performed over time
Revenue
$7.22M
Gross profit
$7.22M
Operating income
-$88.55M
Net income
-$86.77M
Gross margin
100%
Net margin
-1,201.1%
TSHA's operating margin has shrunk by 116% YoY and by 12% QoQ
The gross profit has decreased by 49% YoY and by 13% QoQ
Taysha Gene Therapies's revenue has decreased by 49% YoY and by 13% QoQ
The net margin has contracted by 44% YoY and by 12% from the previous quarter
Price vs fundamentals
How does TSHA's price correlate with its fundamentals
Growth
What is Taysha Gene Therapies's growth rate over time
Valuation
What is Taysha Gene Therapies stock price valuation
P/E
N/A
P/B
10.39
P/S
104.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
74.65
Taysha Gene Therapies's EPS has increased by 31% YoY and by 6% QoQ
TSHA's price to book (P/B) is 121% higher than its last 4 quarters average of 4.7 but 25% lower than its 5-year quarterly average of 13.9
The company's equity fell by 23% QoQ but it rose by 2.2% YoY
TSHA's price to sales (P/S) is 110% more than its last 4 quarters average of 49.6
Taysha Gene Therapies's revenue has decreased by 49% YoY and by 13% QoQ
Efficiency
How efficient is Taysha Gene Therapies business performance
TSHA's ROE has soared by 90% year-on-year and by 3.3% since the previous quarter
The return on invested capital has surged by 84% year-on-year and by 7% since the previous quarter
Taysha Gene Therapies's return on sales has decreased by 49% YoY and by 12% QoQ
Taysha Gene Therapies's return on assets has increased by 35% YoY
Dividends
What is TSHA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TSHA.
Financial health
How did Taysha Gene Therapies financials performed over time
The company's total assets is 66% higher than its total liabilities
Taysha Gene Therapies's quick ratio has surged by 61% YoY but it has decreased by 2.2% QoQ
The current ratio has soared by 58% year-on-year
The debt is 8% more than the equity
Taysha Gene Therapies's debt to equity has increased by 26% QoQ
The company's equity fell by 23% QoQ but it rose by 2.2% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.